LEON : Enabling Nano Now

LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

  • News

[vc_row][vc_column][vc_column_text]LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer, from development stage to commercial scale. The prerequisites to manufacture the LEON reactor in series are therefore met – a milestone achievement on the road to broad application of the NANOnow product platform for the encapsulation of mRNA in lipid nanoparticles.

 

Find out more:

PR LEON Reactor development completed

 

[/vc_column_text][/vc_column][/vc_row]

LEON : Enabling Nano Now

About LEON

Based in Planegg/Munich, leon-nanodrugs GmbH is a pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs).

The company leverages its proprietary FR-JET®  technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services.

LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com